| Issue Date | Title | Author(s) |
| 2024-04 | Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series. | Vagnildhaug, OM; Balstad, TR; Ottestad, I; Bye, A; Greil, C; Arends, J; Baracos, V; Brown, LR; Dajani, OF; Dolan, RD; Fallon, M; Fraser, E; Grzyb, A; Hjermstad, MJ; Jakobsen, G; Kaasa, S; McDonald, J; Philips, I; Sayers, J; Simpson, MR; Sousa, MS; Skipworth, RJE; Laird, BJA; Solheim, TS; Cancer Cachexia Endpoints Working Group, |
| 2024-06 | Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series. | Yule, MS; Thompson, J; Leesahatsawat, K; Sousa, MS; Anker, SD; Arends, J; Balstad, TR; Brown, LR; Bye, A; Dajani, O; Fallon, M; Hjermstad, MJ; Jakobsen, G; McDonald, J; McGovern, J; Roeland, EJ; Sayers, J; Skipworth, RJE; Ottestad, IO; Philips, I; Simpson, MR; Solheim, TS; Vagnildhaug, OM; McMillan, D; Laird, BJA; Dolan, RD; Cancer Cachexia Endpoints Working Group, |
| 2022-06-01 | Body weight (BW) response timing to anamorelin (ANAM) in advanced non–small cell lung cancer (NSCLC)–associated cachexia. | Skipworth, RJE; Walsh, D; Rotaru, DD; Ballinari, G; Currow, DC |
| 2024-06 | Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series. | Brown, LR; Sousa, MS; Yule, MS; Baracos, VE; McMillan, DC; Arends, J; Balstad, TR; Bye, A; Dajani, O; Dolan, RD; Fallon, MT; Greil, C; Hjermstad, MJ; Jakobsen, G; Maddocks, M; McDonald, J; Ottestad, IO; Phillips, I; Sayers, J; Simpson, MR; Vagnildhaug, OM; Solheim, TS; Laird, BJA; Skipworth, RJE; Cancer Cachexia Endpoints Working Group, |
| 2022-06-01 | Cancer cachexia impact on chemotherapy dose reduction, treatment discontinuation, and survival: A qualitative systematic review. | Bonomi, PD; Walsh, D; Currow, DC; Ballinari, G; Skipworth, RJE |
| 2021-01-01 | Does body mass index (BMI) affect the type of response to anamorelin (ANAM) over time? Focus on body composition and anorexia symptoms and concerns | Currow, D; Ballinari, G; Skipworth, RJE |
| 2022-09-01 | EP10.01-016 Cachexia’s Impact on Immunotherapy Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review | Skipworth, RJE; Bonomi, PD; Currow, DC; Ballinari, G; Walsh, D |
| 2023-10 | Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series. | McDonald, J; Sayers, J; Anker, SD; Arends, J; Balstad, TR; Baracos, V; Brown, L; Bye, A; Dajani, O; Dolan, R; Fallon, MT; Fraser, E; Griel, C; Grzyb, A; Hjermstad, M; Jamal-Hanjani, M; Jakobsen, G; Kaasa, S; McMillan, D; Maddocks, M; Philips, I; Ottestad, IO; Reid, KF; Sousa, MS; Simpson, MR; Vagnildhaug, OM; Skipworth, RJE; Solheim, TS; Laird, BJA; Cancer Cachexia Endpoints Working Group, |
| 2024-06 | Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series. | Hjermstad, MJ; Jakobsen, G; Arends, J; Balstad, TR; Brown, LR; Bye, A; Coats, AJS; Dajani, OF; Dolan, RD; Fallon, MT; Greil, C; Grzyb, A; Kaasa, S; Koteng, LH; May, AM; McDonald, J; Ottestad, I; Philips, I; Roeland, EJ; Sayers, J; Simpson, MR; Skipworth, RJE; Solheim, TS; Sousa, MS; Vagnildhaug, OM; Laird, BJA; Cancer Cachexia Endpoints Working Group, |
| 2018-01-01 | Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review | Miller, J; Wells, L; Nwulu, U; Currow, D; Johnson, MJ; Skipworth, RJE |
